Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases

Published: Thursday, April 17, 2014
Last Updated: Thursday, April 17, 2014
Bookmark and Share
Company’s IKKe/TBK1 programme to offer a disease-modifying treatment for COPD patients.

Domainex Ltd. has announced that it has successfully completed a series of laboratory studies examining the in vivo effects of its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation models.

In four separate studies a lipopolysaccharide (LPS) challenge was delivered either to the lungs or systemically to mimic the effect of inflammatory disease.

In these experiments Domainex showed that its orally-delivered compounds can inhibit the expression of a number of pro-inflammatory cytokines including TNF-alpha, RANTES, IL-1-beta, and IL-6, and maintain prolonged activity against many of the cytokines for at least 20 hours.

No side-effects were evident in these studies. These results are extremely promising in the search for new treatments of life-limiting diseases such as chronic obstructive pulmonary disease (COPD).

Domainex’s IKKe/TBK1 programme is first-in-class, and promises to offer a disease-modifying treatment for COPD patients, whereas existing treatments merely provide them with symptomatic relief.

Domainex’s Director of Research, Dr Trevor Perrior said: “These exciting results clearly show that Domainex’s programme on IKKe/TBK1 offers the prospect of new treatments for a number of inflammatory diseases, including psoriasis, rheumatoid arthritis and COPD. It’s also very significant that the compounds can be delivered orally, because in many of these diseases - such as psoriasis and COPD - patients are in great need of effective oral medicines”.

Domainex’s CEO Dr Eddy Littler said: “This is a major achievement by Domainex and we will build upon this success with further in vivo models of inflammatory diseases. Our first disease model will be for COPD, a disease which has high medical need and enormous commercial potential. Our compounds are likely to achieve the highly-attractive profile of being safe, effective, and orally-delivered anti-inflammatory compounds”.

Domainex will continue to study the utility of these compounds as treatments for COPD, and other inflammatory diseases. It hopes to partner the programme soon and to proceed to Phase I Clinical Trials.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domainex and Cresset Announce Drug Discovery Services Alliance
Alliance will give access to the renowned expertise of Domainex in protein expression, biochemical assays and hit identification.
Tuesday, February 02, 2016
University of Warwick Wins Domainex’s First Discovery STAR Award
Domainex Ltd. has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick.
Monday, September 02, 2013
Domainex Wins Genesis Award for its Work in Supporting Translational Research
Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award.
Wednesday, December 15, 2010
Domainex Collaborates with St George’s University and The University of Manchester for Asthma Treatment
The £1.5 million collaboration focuses on a new drug discovery programme to provide a better treatment for asthma.
Friday, July 10, 2009
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!